Boehringer Ingelheim, one of the world’s leading research-driven biopharmaceutical companies, has signed a Memorandum of Understanding (MoU) with Aster DM Healthcare, to collaborate on initiatives that strengthen medical education, patient engagement and disease awareness across Cardio-Renal-Metabolic (CRM) diseases in the UAE.
The signing ceremony was attended by representatives from both organisations, including Rahul Kadavakolu, Group Chief Marketing Officer, Aster DM Healthcare, and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE, and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE, representing Boehringer Ingelheim.
The strategic collaboration reflects a shared commitment to improving patient outcomes through education, prevention and innovation. By combining Aster DM Healthcare's integrated healthcare ecosystem with Boehringer Ingelheim's expertise in Cardio-Renal-Metabolic diseases, the partnership aims to enhance clinical knowledge, empower patients, and support earlier intervention through awareness and screening initiatives.
The collaboration also establishes a framework for future joint initiatives that leverage the strengths of both organizations to address the growing burden of chronic Cardio-Renal-Metabolic diseases. Through educational programmes, patient-centered initiatives and preventive healthcare efforts, Boehringer Ingelheim aims to contribute to a more informed healthcare workforce, empowered patients, and healthier communities across the UAE and Jordan.
